Several trials are experimenting with novel (pan)-RAF inhibitors alone or in combination with MEK, FAK, RAS, or SHP-2 inhibitors in patients with BRAF-V600E solid tumors, including NSCLC refractory to BRAK/MEK-inhibitors or harboring other RAF alterations (BRAF class II and III mutations, RAF gene fusions or amplification) [127] (Table S5). The gene discussed is PTK2; the disease is non-small cell lung carcinoma.